Cargando…
Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma
Adrenocortical carcinoma (ACC) is a rare, but aggressive endocrine malignancy with a generally poor clinical outcome. There is no effective therapy for advanced and metastatic ACC. In our study, we found that an existing drug (rottlerin) exerted its tumour-suppressive function in ACC. Specifically,...
Autores principales: | Zhu, Yi, Wang, Minjie, Zhao, Xu, Zhang, Lei, Wu, Yigao, Wang, Bangqi, Hu, Weilie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410265/ https://www.ncbi.nlm.nih.gov/pubmed/28423559 http://dx.doi.org/10.18632/oncotarget.15221 |
Ejemplares similares
-
Rottlerin and Cancer: Novel Evidence and Mechanisms
por: Maioli, E., et al.
Publicado: (2012) -
Inhibition of Notch-1 pathway is involved in rottlerin-induced tumor suppressive function in nasopharyngeal carcinoma cells
por: Hou, Yingying, et al.
Publicado: (2017) -
Antitumor effect of sunitinib in human prostate cancer cells functions via autophagy
por: Wang, Bangqi, et al.
Publicado: (2017) -
Rottlerin inhibits cell growth and invasion via down-regulation of Cdc20 in glioma cells
por: Wang, Lixia, et al.
Publicado: (2016) -
Rottlerin exhibits antitumor activity via down-regulation of TAZ in non-small cell lung cancer
por: Zhao, Zhe, et al.
Publicado: (2016)